Anthem Biosciences Ltd
NSE: ANTHEM | BSE: 544449
₹774.10
₹15.15
(2.00%)
As on 17-Jul-2026 11:24IST
Market cap
₹42,752 Cr
Revenue (TTM)
₹2,124 Cr
P/E Ratio
72.2
P/B Ratio
14.2
Div. Yield
0.3 %
Quality Score
9/10
Growth Score
8/10
Valuation Score
4/10
Momentum Score
8/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹592 Cr
-
ROE
22 %
-
ROCE
29.6 %
-
Industry P/E
--
-
EV/EBITDA
43
-
Debt to Equity
0
-
Book Value
₹53.6
-
EPS
₹10.5
-
Face value
2
-
Shares outstanding
563,384,760
10 Years Aggregate
CFO
₹1,832.37 Cr
EBITDA
₹3,990.67 Cr
Net Profit
₹2,744.05 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Anthem Biosciences
| 18.8 | 0.6 | 7.0 | -- | -- | -- | -- |
|
BSE Healthcare
| 14.2 | 5.5 | 14.7 | 9.6 | 23.7 | 13.5 | 11.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Anthem Biosciences
|
774.1 | 42,752.5 | 2,124.3 | 591.8 | 32.9 | 22 | 72.2 | 14.2 |
| 8,847.5 | 1,27,770.6 | 25,228.5 | 1,957.7 | 11.5 | 21.1 | 65.8 | 13.5 | |
| 820.7 | 70,731.9 | 4,643.2 | 464.1 | 13.7 | 8.9 | 182.2 | 14.3 | |
| 947.5 | 72,736.4 | 9,127.8 | 1,047.8 | 17.9 | 11 | 69.8 | 7.4 | |
| 115.8 | 499.1 | 0.0 | -0.7 | -- | -3 | -- | 12.5 | |
| 1,323.1 | 35,789.5 | 4,410.2 | 554.1 | 15.8 | 14.5 | 64.3 | 9.0 | |
| 72.1 | 139.7 | 61.5 | 1.1 | 5.2 | -0.3 | 121.4 | 1.9 | |
| 1,088.8 | 1,06,928.7 | 8,373.5 | 1,442.4 | 21.5 | 14.5 | 74.1 | 10.1 | |
| 2,021.9 | 41,493.4 | 7,896.0 | 811.6 | 14.8 | 19.8 | 51.5 | 9.1 | |
| 553.6 | 2,521.9 | 407.3 | 77.5 | 24.0 | 18.9 | 32.5 | 5.6 |
Shareholding Pattern
View DetailsNews & Analysis
All News
Anthem Biosciences IPO analysis
5 min read•By Abhinav Goel
About Anthem Biosciences
Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients.... The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial manufacturing of RNA-based therapies, antibody-drug conjugates, peptides and oligonucleotides, lipids, biologics and biotherapeutics, fermentation, biosynthesis and biotransformation, and flow chemistry. It also manufactures and sells complex specialized fermentation-based active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2; microbial and mammalian biosimilars; probiotics, such as bacillus species, lactobacillus species, bifidobacterium species, streptococcus species and saccharomyces boulardii; enzymes; peptides, including semaglutide, plecanatide, linaclotide, liraglutide, and cilengitide; nutritional actives, vitamin analogues, and APIs. The company was incorporated in 2006 and is based in Bengaluru, India. Read more
-
Incorporated
2006
-
Chairman
Ajay Bhardwaj
-
Managing Director
Ajay Bhardwaj
-
Headquarters
Bengaluru, Karnataka
-
Website
Looking for more details about Anthem Biosciences Ltd’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
Announcements
View AnnouncementsNo News & Announcements are available.
FAQs for Anthem Biosciences
What is the current share price of Anthem Biosciences Ltd Today?
The share price of Anthem Biosciences Ltd is ₹774.10 (NSE) and ₹774.45 (BSE) as of 17-Jul-2026 11:24 IST. Anthem Biosciences Ltd has given a return of --% in the last 1 years.
What is the current PB & PE ratio of Anthem Biosciences Ltd?
The P/E ratio of Anthem Biosciences Ltd is 72.24 times as on 16-Jul-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2026
|
62.29
|
12.25
|
|
2025
|
0.00
|
0.00
|
|
2024
|
0.00
|
0.00
|
|
2023
|
0.00
|
0.00
|
|
2022
|
0.00
|
0.00
|
What is the 52 Week High and Low of Anthem Biosciences Ltd?
The 52-week high and low of Anthem Biosciences Ltd are Rs 873.50 and Rs 579.15 as of 17-Jul-2026.
What is the market cap of Anthem Biosciences Ltd?
Anthem Biosciences Ltd has a market capitalisation of ₹ 42,752 Cr as on 16-Jul-2026. As per SEBI classification, it is a Mid Cap company.
Should I invest in Anthem Biosciences Ltd?
Before investing in Anthem Biosciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.